P-glycoprotein recognition of substrates and circumvention through rational drug design

被引:183
作者
Raub, Thomas J. [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
关键词
active efflux; circumvention; drug resistance; drug membrane transport; P-glycoprotein; structure-activity relationship;
D O I
10.1021/mp0500871
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It is now well recognized that membrane efflux transporters, especially P-glycoprotein (P-gp; ABCB1), play a role in determining the absorption, distribution, metabolism, excretion, and toxicology behaviors of some drugs and molecules in development. An investment in screening structure-activity relationship (SAR) is warranted in early discovery when exposure and/or target activity in an in vivo efficacy model is not achieved and P-gp efflux is identified as a rate-limiting factor. However, the amount of investment in SAR must be placed into perspective by assessing the risks associated with the intended therapeutic target, the potency and margin of safety of the compound, the intended patient population(s), and the market competition. The task of rationally designing a chemistry strategy for circumventing a limiting P-gp interaction can be daunting. The necessity of retaining biological potency and metabolic stability places restrictions on what can be done, and the factors for P-gp recognition of substrates are complicated and poorly understood. The parameters within the assays that affect overall pump efficiency or net efflux, such as passive diffusion, membrane partitioning, and molecular interaction between pump and substrate, should be understood when interpreting data sets associated with chemistry around a scaffold. No single, functional group alone is often the cause, but one group can accentuate the recognition points existing within a scaffold. This can be likened to a rheostat, rather than an on/off switch, where addition or removal of a key group can increase or decrease the pumping efficiency. The most practical approach to de-emphasize the limiting effects of P-gp on a particular scaffold is to increase passive diffusion. Efflux pumping efficiency may be overcome when passive diffusion is fast enough. Eliminating, or substituting with fewer, groups that solvate in water, or decreasing their hydrogen bonding capacity, and adding halogen groups can increase passive diffusion. Reducing molecular size, replacing electronegative atoms, blocking or masking H-bond donors with N-alkylation or bulky flanking groups, introducing constrained conformation, or by promoting intramolecular hydrogen bonds are all examples of steps to take. This review discusses our understanding of how P-gp recognizes and pumps compounds as substrates and describes cases where structural changes were made in a chemical scaffold to circumvent the effects of P-gp interactions.
引用
收藏
页码:3 / 25
页数:23
相关论文
共 50 条
[21]   Role of P-glycoprotein in statin drug interactions [J].
Holtzman, Carol W. ;
Wiggins, Barbara S. ;
Spinler, Sarah A. .
PHARMACOTHERAPY, 2006, 26 (11) :1601-1607
[22]   Clinical relevance of P-glycoprotein in drug therapy [J].
Lin, JH ;
Yamazaki, M .
DRUG METABOLISM REVIEWS, 2003, 35 (04) :417-454
[23]   New Insight into P-Glycoprotein as a Drug Target [J].
Breier, Albert ;
Gibalova, Lenka ;
Seres, Mario ;
Barancik, Miroslav ;
Sulova, Zdenka .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (01) :159-170
[24]   Multidrug Resistance Through the Spectacle of P-Glycoprotein [J].
Goda, Katalin ;
Bacso, Zsolt ;
Szabo, Gabor .
CURRENT CANCER DRUG TARGETS, 2009, 9 (03) :281-297
[25]   Structure-activity relationship of P-glycoprotein substrates and modifiers [J].
Seelig, A ;
Landwojtowicz, E .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 12 (01) :31-40
[26]   Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo [J].
Cornaire, G ;
Woodley, J ;
Hermann, P ;
Cloarec, A ;
Arellano, U ;
Houin, G .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 278 (01) :119-131
[27]   Computational models for identifying potential P-glycoprotein substrates and inhibitors [J].
Crivori, Patrizia ;
Reinach, Benedetta ;
Pezzetta, Daniele ;
Poggesi, Italo .
MOLECULAR PHARMACEUTICS, 2006, 3 (01) :33-44
[28]   ANTIESTROGENS AND STEROID-HORMONES - SUBSTRATES OF THE HUMAN P-GLYCOPROTEIN [J].
RAO, US ;
FINE, RL ;
SCARBOROUGH, GA .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (02) :287-292
[29]   Study Models of Drug-Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels [J].
Veiga-Matos, Jessica ;
Morales, Ana I. ;
Prieto, Marta ;
Remiao, Fernando ;
Silva, Renata .
MOLECULES, 2023, 28 (22)
[30]   Development and characterization of an open tubular column containing immobilized P-glycoprotein for rapid on-line screening for P-glycoprotein substrates [J].
Moaddel, R ;
Bullock, PL ;
Wainer, IW .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 799 (02) :255-263